Whole genome methylation analysis of nondysplastic Barrett esophagus that progresses to invasive cancer by Dilworth, Mark P et al.
 
 
Whole genome methylation analysis of
nondysplastic Barrett esophagus that progresses to
invasive cancer
Dilworth, Mark; Nieto, Tom; Stockton, Jo D; Whalley, Celina; Tee, Louise; James, Jonathan;
Noble, Fergus; Underwood, Tim J; Hallissey, Michael T; Hejmadi, Rahul; Trudgill, Nigel;
Tucker, Olga; Beggs, Andrew
DOI:
10.1097/SLA.0000000000002658
Document Version
Peer reviewed version
Citation for published version (Harvard):
Dilworth, MP, Nieto, T, Stockton, JD, Whalley, CM, Tee, L, James, JD, Noble, F, Underwood, TJ, Hallissey, MT,
Hejmadi, R, Trudgill, N, Tucker, O & Beggs, AD 2018, 'Whole genome methylation analysis of nondysplastic
Barrett esophagus that progresses to invasive cancer', Annals of surgery.
https://doi.org/10.1097/SLA.0000000000002658
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Checked for eligibility: 21/03/2018
Please note this is not the final version.
Dilworth, Mark P., et al. "Whole Genome Methylation Analysis of Nondysplastic Barrett Esophagus that Progresses to Invasive Cancer."
Annals of surgery (2018).
https://insights.ovid.com/crossref?an=00000658-900000000-95724
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
 Title: Whole genome methylation analysis of non-dysplastic Barrett’s oesophagus 
that progresses to invasive cancer 
Authors: Dilworth MP FRCS(Gen) *,1, Nieto T MRCS*,1, Stockton JD PhD1, Whalley C 
MSc1, Tee L MSc1, James JD PhD1, Noble F MRCS5, Underwood TJ FRCS(Gen)5, 
Hallissey MT FRCS2, Hejmadi R FRCPath1, Trudgill N FRCP3, Tucker O FRCS*,4, 
Beggs AD FRCS(Gen) PhD*,1,2 
1. Institute of Cancer and Genomic Science, University of Birmingham, U.K.  
2. Queen Elizabeth Hospital, Birmingham, U.K.  
3. Sandwell and West Birmingham NHS Trust, Birmingham, U.K.  
4. Heart of England NHS Trust, Birmingham, U.K.   
5. Cancer Sciences Unit, Faculty of Medicine, University of Southampton, 
Southampton, U.K.  
* - these authors contributed equally to this study.  
Corresponding author: 
Dr Andrew D Beggs, 
Institute of Cancer & Genomic Science 
University of Birmingham 
Vincent Drive 
Birmingham 
B15 2TT 
 Email: a.beggs@bham.ac.uk  
Telephone: +44 (0)121 414 7458 
Reprints will not be available 
Funding support: AB acknowledges funding from the Wellcome Trust 
(102732/Z/13/Z), Cancer Research UK (C31641/A23923) and the Medical Research 
Council (MR/M016587/1). AB also acknowledges support from the University of 
Birmingham Human Biomaterials Resource Centre. MPD and TN acknowledge 
funding from the QE Hospital Charities.TJU acknowledges funding by the Medical 
Research Council (G1002565) and Cancer Research UK (C10104/A23924). TJU 
thanks the University of Southampton CRUK/ECMC Tissue Bank.  
Running head: Epigenetics of Barrett’s oesophagus 
 
  
 MINI-ABSTRACT: 
Identifying patients with Barrett’s oesophagus (BO) who progress to adenocarcinoma 
amenable to surgical treatment remains a challenge. In order to investigate this 
cohort, we carried out analysis of the epigenome of “progressive” vs. “non-
progressive” BO finding significant epigenetic variation between these groups that 
identified new pathways for therapy & diagnosis. 
 
ABSTRACT 
Objective:  To investigate differences in methylation between patients with non-
dysplastic Barrett’s’ oesophagus who progress to invasive adenocarcinoma and 
those who do not. 
Summary background data: Identifying patients with non-dysplastic Barrett’s 
oesophagus who progress to invasive adenocarcinoma remains a challenge. 
Previous studies have demonstrated the potential utility of epigenetic markers for 
identifying this group.   
Methods:  A whole genome methylation interrogation using the Illumina 
HumanMethylation 450 array of patients with non-dysplastic Barrett’s Oesophagus 
who either develop adenocarcinoma or remain static, with validation of findings by 
bisulfite pyrosequencing 
Results:  In total, 12 patients with “progressive” vs. 12 with “non-progressive” non-
dysplastic Barrett’s oesophagus were analysed via methylation array. Forty-four 
methylation markers were identified that may be able to discriminate between non-
 dysplastic Barrett’s Oesophagus that either progress to adenocarcinoma or remain 
static.  Hypomethylation of the recently identified tumour suppressor OR3A4  (probe 
cg09890332) validated in a separate cohort of samples (median methylation in 
progressors = 67.8% vs. 96.7% in non-progressors, p=0.0001, z = 3.85, Wilcoxon 
rank sum test) and was associated with the progression to adenocarcinoma. There 
were no differences in copy number between the two groups, but a global trend 
towards hypomethylation in the progressor group was observed.  
Conclusion:  Hypomethylation of OR3A4 has the ability to risk stratify the patient with 
non-dysplastic Barrett’s Oesophagus and may form the basis of a future surveillance 
program.  
Keywords: Barrett’s oesophagus; Oesophageal cancer; Methylation; Cancer 
Genetics 
  
 INTRODUCTION 
Oesophageal adenocarcinoma (OADC) incidence is increasing 1 and currently 
represents 5% of the digestive tract cancers in the UK 2.  Overall disease survival is 
poor 3 but correlates with stage of cancer at presentation, demonstrating significant 
survival advantages with detection of early stage disease 4, 5. 
Barrett’s Oesophagus (BO), in which normal squamous mucosa is replaced with a 
metaplastic columnar phenotype, results from prolonged exposure to stomach acids 
and bile salts which reflux into the oesophagus causing chronic inflammation and 
tissue damage 6.   
The incidence of BO is increasing, largely thought to be a consequence of obesity 
induced reflux disease 7-10.   Barrett’s oesophagus is associated with an increased 
risk of OADC 11, but for the majority of patients, BO will never progress beyond 
simple benign metaplasia 12, 13.  However, in a small number of patients, dysplasia 
will develop with some progressing to OADC 14.  The incidence of OADC in the BO 
population is up to 150 times greater than unaffected individuals 12. 
Although the pathological changes seen in Barrett’s adenocarcinoma are understood 
as part of a well-established metaplasia-dysplasia-carcinoma sequence 15, the 
molecular drivers are less clear16-18.  The current dilemma is that for patients with 
non-dysplastic BO, there are no accurate methods for identifying the small number of 
patients at high risk of progression to cancer.   
Surveillance practice of the Barrett’s patients varies widely, between some who 
endoscope patients each year in contrast to others who will never repeat the 
investigation19.  The on-going UK Medical Research Council funded BOSS study 
 aims to understanding the optimum surveillance strategy, randomising between 
prospective monitoring BO patients with frequent endoscopic assessment or a “watch 
and wait” policy 20. 
Clearly, there is need for a method of risk stratification in these patients in order to 
facilitate a streamlined surveillance programme by identifying high risk non-dysplastic 
BO patients. Attempts at biomarker development for stratification of high risk Barrett’s 
oesophagus have focused on mutational change, specifically around the role of TP53 
mutation in predicting “high risk” disease 21 given its role as a driver in oesophageal 
cancer. However Ross-Innes et al 17 have convincingly demonstrated the presence of 
pathogenic TP53 mutations in apparently normal squamous oesophageal mucosa 
thus making its role in progression to invasive adenocarcinoma unclear.  However, 
the role of epigenetic change in the pathogenesis of Barrett’s oesophagus and 
oesophageal cancer is less well understood, but may well happen much earlier in the 
cancer development pathway and, as a direct result, provide a more appropriate 
target for both predicting its development and potentially arresting tumourigenesis, 
should a suitable epigenetic modulator be identified.  
Multiple methylation markers have been identified which can discriminate between 
high risk and low risk BO including APC/ p16  22, MGMT 23, PKP-1 24, TIMP3/TERT 
25, RUNX3/HPP1 26 27 and AKAP12  28.  Agarwal et al 29 performed a MeCIP array 
based approach to compare the methylomes of progressor (n=5) vs. non-progressing 
patients (n=4).  In patients who progressed to invasive adenocarcinoma, their original 
biopsies began either with no dysplasia, indefinite dysplasia or low-grade dysplasia, 
making comparison difficult.  However, subsequent analysis of the top 25 differential 
methylation patterns found three gene regions with hypermethylation amongst the 
 progression group (Pro_MMD2, Pro_ZNF358 and Intra_F10) with a trend towards 
global hypomethylation, in keeping with other epithelial pre-malignant conditions 30.  
Kaz et al 31 also found significant differences in methylation in patients with BO due 
to factors such as obesity, smoking and gender which may be responsible for some 
of the observed risk.  
While the studies reviewed do show variation in methylation between progressive vs. 
non-progressive BO, the methodology has been heterogeneous and few have 
conducted the study with a group of the same patients tracked over time.   
 
AIMS  
To determine whether there are differences in methylation in patients between high 
risk non-dysplastic Barrett’s Oesophagus which will progress to cancer vs low risk 
Barrett’s  
 
 
 
 
  
 METHODS 
Patients and Samples: 
Two sample cohorts were identified containing patients who either progressed to 
OADC from non-dysplastic BO or remained with non-dysplastic BO (NDBO) identified 
from a prospectively maintain database of patients with BO at a large district general 
hospital.  Inclusion criteria for the study were progressing patients with non-dysplastic 
Barrett’s oesophagus who, when observed over the study period, developed OADC.  
Samples were only included where there was a NDBO biopsy and then histology 
evidence that the patient developed adenocarcinoma.   Non-progressing patients 
were identified from a biopsy of NDBO which when followed over time never 
progressed beyond NDBO.  To be included in this group, the patient must have been 
in a surveillance programme for a minimum of 15 years and have serial biopsies over 
that period.  Patients within the surveillance programme had endoscopy and biopsy 
every 2 years32. Biopsies were taken at the time of the initial surveillance endoscopy 
and at all subsequent endoscopies including immediately prior to treatment as part of 
their staging.  They were also required to have still been alive and to have had a 
NDBO biopsy within 2 years of this study.  
Patients were excluded from the study if BO material was only available as part of 
tumour associated BO or if dysplasia was identified in any BO biopsies.  
All tissue used was formalin fixed paraffin embedded (FFPE) samples obtained from 
pathology libraries and prepared by the University of Birmingham Human 
Biomaterials Resource Centre (ethical approval 09/H1010/75). H&E stained slides 
were reviewed by a consultant pathologist to ensure that the samples were BO and 
 had no dysplasia throughout their extent. Cut 5M paraffin sections were mounted 
onto frosted slides, and macrodissection for BO carried out. DNA extraction was then 
performed using Qiagen DNeasy Blood and Tissue kit following the manufacturer’s 
protocol. Each sample of extracted DNA was then quantified and qualified by 
Nanodrop spectrophotometry and Qubit fluorimetry. Bisulphite conversion was 
performed using a Zymo DNA Methylation bisulphite conversion kit following the 
modified Illumina Infinium protocol on 500ng of extracted DNA. .     
 
Methylation Arrays 
The Illumina HumanMethylation 450 array, in which the methylation status of more 
than 485,000 individual CpG sites are examined 33 was used to compare sample 
groups (progressing NDBO vs non-progressing NDBO).  Once bisulphite converted, 
1ng of DNA was quality controlled (Illumina FFPE QC kit) with only samples with dCt 
<5 being taken forward to array analysis. The resulting samples underwent repair 
suitable for array hybridisation using the Illumina FPPE restore kit.  34 followed by 
hybridisation to Illumina HumanMethylation450 arrays using manufacturers protocols 
and scanned on an Illumina iScan. Normalised intensity files (iDAT) were exported 
using GenomeStudio for downstream analysis.  
Immunohistochemistry 
IHC was carried out on a Leica Bond RX system using a mouse polyclonal anti-
OR3A4 antibody (Abcam ab67107) at a dilution of 1:100 with a primary incubation 
time of 15 minutes.  
 IHC was scored on epithelial and stromal components and a composite score 
consisting of the sum of expression within membranous, nuclear and cytoplasmic 
compartments on a score of 1-4 was made, giving a combined maximum possible 
score of 12 for each compartment. Scoring was carried out by two independent 
observers blinded to progressor/non-progressor status.  
Bioinformatics Analysis of Array Data 
Bioinformatics analysis of the methylation microarrays was carried using the ChAMP 
package 35 via Bioconductor/R.  In brief, red/green intensity values were captured 
from Illumina iDAT files, background corrected and SWAN normalised to produce M 
values (further details given in supplementary methods).  
M values were analysed using a logistic regression model using Empirical Bayesian 
shrinkage of moderated t-statistics to correct for small sample size. Small sample 
size was controlled for by setting stringent FDR Q-values of <0.05.  Identification of 
variable methylated sites allowed the CpG site markers to be highlighted.  DNA Copy 
number analysis was carried out using the DNAcopy module of ChAMP.  
 
Pyrosequencing validation of hits 
Methylation insensitive primers were designed and sourced, using Qiagen PyroMark 
Primer Design software v2.0.  Primers were designed to flank CpG sites of interest.  
Illumina CG methylation probe locations were retrieved from the UCSC genome 
browser 36 and FASTA sequence retrieved for -200bp to + 200bp of the target CG 
dinucleotide.  Primer design settings were optimised to design amplicons suitable for 
 FFPE pyrosequencing, with the optimum amplicon size set to between 80-150bp.  All 
other settings were as per the standard Qiagen design parameters.  Primers were 
ordered from Sigma Aldrich, with the biotinylated pyrosequencing primer being 
purified by high performance liquid chromatography and the remainder by desalting. 
Pyrosequencing PCR was performed using Qiagen PyroMark PCR Gold kit, 
consisting of 2uL of bisulphite converted DNA, 25uL of PCR master mix, 5uL of 
CoralLoad dye, 3uL MgSO4,  10uL of Q reagent and 2.5uL each of forward (20mM) 
and reverse (20mM) primer. Reaction conditions were determined experimentally by 
use of a gradient PCR for each primer pair. A typical reaction consisted of activation 
at 95C for 15 minutes, followed by 45 cycles of denaturation at 94C for 30s, 
annealing at 56C for 30s and extension at 72C for 30 seconds, followed by a final 
extension step at 72C for 10 minutes. In addition to experimental DNA, each PCR 
was performed with 100% methylated DNA, 100% un-methylated DNA and ddH2O 
as controls. Methylated and unmethylated DNA was generated in house by means of 
M.SSl conversion (methylated DNA) and whole genome amplification using the 
Qiagen Repli-G kit (unmethylated DNA).  Primer sequences for validation 
pyrosequencing were as follows. For FGFR2 cg17337672 these were Forward = 
AGGGGAAGGGAATTTAGGTT; Reverse = 
[Btn]TCAATCTTCCCCCAAACAACCACT  and sequencing = 
GTTTAGAAGTTTTTTTTGGATTAGT. For ORA3A4 cg07863524 these were forward 
= GTGGTAGAAGTAGGATGAGGTGTTGATAAT; Reverse 
=[Btn]CTTCAACTTCCTTCCCCTTACATTT and sequencing = 
GGGTAGGGATGGAAGA . For OR3A4 cg09890332 these were Forward = 
TTAAAGTGTTAGGATTATAGGTGTGAGTTA, reverse = 
 [Btn]TTTCCCAACCCTAATCACTACTAATAAAAT and sequencing = 
GGATTATAGGTGTGAGTTAT. 
RESULTS: 
Patient selection: 
In total, 67 patients were recruited, 37 from Sandwell and West Birmingham NHS 
Trust (SWBNT) and 30 from University Hospital Birmingham NHS Trust (UHBFT). Of 
these, 20/67 progressed from non-dysplastic Barrett’s oesophagus and 47 did not. 
The age range was between 42-60 years with a median age of 56 years of which 
60/67 (89.6%) were of male gender. The median time to diagnosis of OADC in 
“progressor” patients was 114 months, with a range of 14-162 months.  Of the 
patients recruited, in the SWBNT group 6 progressors and 6 non-progressors and in 
the UHBFT 6 progressors and 6 non-progressors were taken forward to methylation 
array analysis, giving a total of 12 progressors and 12 non-progressors. This samples 
size was chosen because of our previous experience with biomarker discovery in 
methylation arrays as a suitable size for biomarker discovery. A validation cohort of 
32 patients (progressors=18, non-progressors=14) were obtained from University 
Hospital Southampton. All patients included in the study had symptoms of reflux 
disease as a presenting symptom. For all patients in the progressor cohort (n=30) the 
observed pathological disease stages at the time of resection were high grade 
dysplasia (4/30, 13%), T1N0 (10/30, 33%), T1N1 (1/30, 3%), T2N0 (2/30, 7%), T2N1 
(3/30,10%), T3N0 (6/30, 20%) and T3N1 (4/30, 13%). All patients with high grade 
dysplasia underwent endoscopic mucosal resection and the remainder underwent 
oesophagectomy. All patients recruited had validation pyrosequencing performed.  
 Methylation microarray analysis 
Twenty four samples in total were hybridised successfully to Illumina 
HumanMethylation450 microarrays. All arrays passed manufacturers QC as specified 
by metrics in Illumina GenomeStudio.  Differential methylation analysis at the probe 
level (Table 1) revealed significant differences in methylation between progressor 
and non-progressors in non-dysplastic BO (Figure 1). In total, 44 significantly 
(defined as Bayes Factor, BF>5, chosen as it is equivalent to a genome wide p-value 
significance of 1x10-6) differentially methylated targets were identified, the bulk being 
hypomethylated, with a trend towards global hypomethylation in progressor samples 
as demonstrated by left-shift of the Volcano plot (Figure 1).  
Differential methylation at the probe level  
The top ranked differentially methylated probe was cg09890332 (chr17:3212495-
3212495, hg19 coordinates) which tags a CpG dinucleotide -1044bp upstream of the 
transcription start site of the long non-coding RNA, OR3A4 (NRR_024128.1). The 
second highest ranked differentially methylated probe was cg24007926 
(chr2:206842761-206842761, hg19 coordinates). This CpG dinucleotide is within a 
large, intragenic region, with the nearest gene being INO80D (INO80 complex 
subunit D, NM_017759.4), 15,684bp downstream of this CpG.  The third highest 
ranked differentially methylated probe was cg17337672 (chr10:123354172-
123354172) which tags a CpG dinucleotide within intron 2 of FGFR2 (Fibroblast 
growth factor receptor 2, NM_000141.4).  
Differentially methylated regions (DMR) were called between progressors and non-
progressors via the dmrLasso function of the CHAMP software package (Table 2). 
 Significant DMRs were found from chr2:503065-503193 (which tags an intragenic 
region, DMR p= 7.69x10-4), chr5:8217236-8217322 (which also tags an intragenic 
region, DMR p=1.27x10-3) and chr10: 123353418- 123355576 which spans a region 
from the 5’ UTR of FGFR2 to the 1st exon within FGFR2 (DMR p=4.79x10-3). 
We took advantage of the information provided by the two colour Illumina Infinium 
chemistry to call copy number aberrations (CAN) within the regions targeted by the 
methylation probes using the CNA calling function of CHAMP. This did not 
demonstrate any recurrent copy number alterations between progressors and non-
progressors. There were no significant differences in the numbers of CNA between 
the two groups, with a median of 43 CNA (range 24-92) in the progressors vs. 44 
CAN (range 30-52) in the non-progressors (p=1.0, Wilcoxon rank sum). 
Pathway methylation analysis was carried out using DAVID. Initially KEGG pathway 
analysis showed that genes associated with MAPK signalling were enriched in the 
dataset (p=0.012). Gene ontology analysis using the UP_KEYWORDS feature 
showed significant enrichment for the disease mutation (p=9.6x10-6), polymorphism 
(p=1.7x10-5), glycoprotein (p=3.4x10-5), and alternate splicing (p=1.1x10-4) terms.  
Validation pyrosequencing 
Because of the likely biological relevance of FGFR2, and the data demonstrating that 
OR3A4 was the top differentially methylated CpG, validation pyrosequencing was 
carried out on all 67 patients. Normality of distribution of methylation values was 
ascertained by histogram plots, in which it was found that methylation was non-
normally distributed, therefore non-parametric testing was carried out 
 For OR3A4 cg09890332, median methylation was 67.8% (IQR = 12.1) in progressors 
vs. 96.7% (IQR 16.1) in non-progressors (p=0.0001, z = 5.158, Wilcoxon rank sum 
test) (Figure 2). The pyrosequencing assay design used covered two additional CpG 
+4bp and +10bp downstream of cg09890332. Median methylation in these was 
66.8% and 59.7% in progressors vs. 75.0% and 68.1% in non-progressors (p=0.0280 
and 0.0368, z=2.197 and 2.088, Wilcoxon rank sum test). In order to investigate 
whether this phenomenon was localised to this region or was a gene-wide 
phenomenon, an additional pyrosequencing assay was designed based on probe ID 
cg07863524 (chr17:3213471-3213471) which is +976bp downstream from 
cg09890332 and -68bp from the TSS of OR4A4. This demonstrated that median 
methylation was 62.2% in progressors and 56.7% in non-progressors (p=0.600, z=-
0.524, Wilcoxon rank sum test). A temporal analysis of change in methylation of 
cg09890332 over time is shown in Figure 3, showing that the difference between 
methylation levels at initial biopsy is static between progressors and non-progressors 
and that the difference is maintained over time and is detectable for an extended 
period of time before diagnosis of OADC.  
We then validated cg17337672 within FGFR2, finding that median methylation was 
83.4% in progressors vs. 82.2% in non-progressors (p=0.51,z=0.653, Wilcoxon rank 
sum test). 
Expression of OR3A4 in progressors vs. non-progressors 
We then carried out Immunohistochemical assessment of expression of OR3A4 
(Figure 4), which, although is labelled as long non-coding RNA is actually expressed 
in tissues (see supplementary results), in a subset of 12 patients.  For the stromal 
 compartment, a median expression of 6 (IQR 4-7) was seen in progressors and 2 
(IQR 1-3) in non-progressors (Wilcoxon rank sum p=0.0308, z=-2.160). For the 
epithelial compartment, a median expression of 8 (IQR 8-10) was seen in 
progressors and 5.5 (IQR 3-10) in non-progressors (Wilcoxon rank sum p=0.4587, 
z=-0.741).  Percentage methylation at OR3A4 and stromal expression was strongly 
negatively correlated (Pearson correlation coefficient = -0.85, p=0.014) and a similar, 
but non-significant correlation was observed with epithelial expression and 
methylation at OR3A4 (Pearson correlation coefficient = -0.40, p=0.373).  
Ability of OR3A4 methylation to act as a discriminator in BO 
In order to understand the accuracy of using methylation within cg09890332 of 
OR3A4 as a biomarker for high-risk Barrett’s oesophagus we carried out a 
multivariable reverse stepwise logistic regression analysis of methylation at the three 
tagged CpG dinucleotides within the pyrosequencing assay as the independent 
variables and progressor vs. non-progressor status as the dependent variable. In this 
model, CpGs two and three became non-significant (p=0.3325 and p=0.4764) and 
were removed from the model, leaving the first CpG in cg09890332 as being 
significant (coef =-0.0563, SE=0.016, z=-3.40,p=0.001,95% CI -0.089- -0.024). Using 
ROC modelling the AUC of this model was 0.82 (95% CI 0.80-0.83) in the cohort 
where the marker was originally generated (Supplementary figure 2).   
We then used the diagt function of Stata 11.2 to model a set methylation threshold 
effect on sensitivity and specificity of the test, aiming for maximum negative 
predictive value and correcting for an incidence rate within the cohort of 0.7%. 
Modelling at a threshold of below 89% being significant showed that hypomethylation 
 at OR3A4 can predict progression to invasive carcinoma with a sensitivity of 70.8%, 
specificity of 86%, positive predictive value of 85% and negative predictive value of 
72.5%.  
We then carried out validation bisulphite pyrosequencing on a cohort of progressors 
(n=18) vs. non-progressors (n=14, Southampton cohort), finding that there were 
significant differences (p=0.0477, unpaired t-test) in methylation with an average 
methylation of 59.2% (95%CI 56.2-62.1%) in progressors vs. 63.5% (95% CI 60.2-
66.7%) in the non-progressors. Regression model demonstrated AUC = 0.70 and 
adjustment for a prevalence of 0.7% using a threshold of 58% demonstrated a 
sensitivity of 33.3%, specificity of 78.6%, positive predictive value of 10.5% and 
negative predictive value of 94%.  
CONCLUSIONS 
We have identified that hypomethylation at cg09890332 corresponding to the CG 
nucleotide at position (CHR) of OR3A4 can discriminate between patients who 
progress from non-dysplastic Barrett’s oesophagus and those who did not. This 
association is maintained across independent cohorts, and seems to be related 
temporally (i.e. the association is maintained in the earliest set of samples from a 
time series of follow-up biopsies in patients with Barretts oesophagus) as well as by 
case status. Gastro-oesophageal reflux is a key risk factor in the development of 
Barretts oesophagus 19 as well as obesity and cigarettes smoking. 
The effect of hypomethylation on the OR3A4 gene seems to be functional, in that 
immunohistochemistry reveals an increase in OR3A4 expression in samples with 
hypomethylation. The finding that the stromal expression in particular is increased is 
 of interest given the known effect of “pathological” stroma in the pathogenesis of 
oesophageal cancer37. Our observed region coincides within 225bp of a CTCF and 
RAD21 transcription factor binding site, further suggesting that methylation there has 
a functional effect to prevent transcription factor binding and alter gene expression.  
Guo et al 38 performed a genome wide screen of long non-coding RNAs in gastric 
adenocarcinoma, finding that OR3A4 was significantly (55.9 fold,) over-expressed in 
these patients. They also observed that levels of OR3A4 were correlated with 
metastatic potential and prognosis. Furthermore, they utilised OR3A4 over-
expression vectors and performed siRNA knockdown to demonstrate that OR3A4 
seems to regulate cellular proliferation in gastric cancer cell lines. Finally, they 
utilised their over-expressing cell line models and implanted them into nude mice, 
finding that OR3A4 over-expressing gastric cancer cell lines grew significantly faster 
and more aggressively than with knockdown of OR3A4. Downstream analysis of 
target genes demonstrated that OR3A4 targets PDLIM2, a putative tumour 
suppressor than regulates cell cycle and adhesion; PIWIL1, a transcriptional silencer 
and DLX4 which induces epithelial-mesenchymal transition via TWIST1.   
We found both at the individual probe level and as part of a differentially methylated 
region that there is hypomethylation in the CpG island associated with FGFR2, 
however this did not validate at the single probe level when examined with bisulphite 
pyrosequencing.  FGFR2 has been observed to undergo recurrent alteration in both 
oesophageal adenocarcinoma 39 and squamous cell carcinoma 40 with the latter 
demonstrating recurrent amplification. The disparity between our microarray results 
and validation by pyrosequencing may be due to probe inflation caused by small 
 sample size, and is a significant weakness of our study however given its biological 
associations with oesophageal adenocarcinoma further work is needed.  
In common with pre-malignant lesions in cancer, such as colorectal adenomatous 
polyps 30, we observed a trend towards genome wide hypomethylation as 
demonstrated by a leftward shift of our genome wide volcano plot, suggesting a 
widespread over-expression of genes as part of the development towards 
malignancy.  We also found no difference in chromosomal instability between 
progressors and non-progressors, although there was widespread instability within 
both sets of samples, in common with what has previously been observed  41 in 
Barrett’s oesophagus.  
Another weakness of our study is the inability to carry out a more comprehensive 
validation of all observed markers as part of a larger panel of markers. Our study 
made use of extremely small tissue biopsies from endoscopic surveillance 
programmes, that limited the quantity of usable DNA that could be extracted from 
these samples and used for downstream validation and thus validation of the 
observed DMR and other DMP regions could not be carried out. We were also limited 
in the number of samples that could be tested, because of the rarity of biopsy 
samples prior to the diagnosis of oesophageal cancer, as we took advantage of a 
local screening programme to obtain samples. However, in both the genome-wide 
and in the validation phase we believe we have sufficient power to detect methylation 
changes in this marker. In the genome-wide phase, our sample size of 24 patients 
would allow us to detect a methylation difference 42 of 2% with a statistical power of 
90%. Similarly, in the validation phase, our sample size would allow us to detect a 
 minimum methylation change of 10% in the sample set given the previously observed 
median methylation and standard deviation in these samples.  
We observed an median time to diagnosis of oesophageal adenocarcinoma on 
commencement of the surveillance program of 114 months, which we believe is a 
reflection of the early identification of these patients and their enrolment into a 
screening programme and the known slow progression of oesophageal 
adenocarcinoma. A further problem with molecular genetic analysis is heterogeneity, 
due to the low proportion of cells within a biopsy specimen that contain changes 
compatible with Barrett’s oesophagus, which leads to less clear methylation changes. 
Hypomethylation of OR3A4, although seemingly accurate for the detection of 
progression of Barrett’s to invasive adenocarcinoma, is likely to be of more utility as a 
multi-modal stratifier in Barrett’s oesophagus, taking account of previous findings at 
the mutational and copy number level, as well as epigenetic change.  However, for 
the purpose of designing a surveillance programme with the ability to risk stratify the 
non-dysplastic Barrett’s oesophagus patient, this marker has significant potential 
utility.  
Development of a streamlined surveillance programme could lead to cost savings 
through the avoidance of un-necessary upper gastro-intestinal endoscopy or via a 
less invasive technology such as the CytoSponge 43, in a low risk cohort identified by 
a molecular marker panel.  More frequent endoscopy in the high risk cohort could 
lead to earlier diagnosis of OADC or initiate management of BO to arrest further 
progression.  In conclusion, development of a stratified marker panel in the context of 
a clinical trial is now needed to improve diagnosis of high risk BO.   
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 Figure legends: 
Figure 1: Volcano plot of probe-level methylation in progressors vs. non-progressors. 
Blue points = Bayes factor < 5; Red points = Bayes factor > 5. The plot shows a 
leftward shift of probes towards the left, suggesting global hypomethylation.  
Figure 2: Boxplot of OR3A4 methylation differentiating high risk non-dysplastic BO 
Figure 3: Change in methylation across temporally acquired samples for OR3A4. The 
y-axis shows percentage methylation at cg09890332 as observed by 
pyrosequencing. Timepoints on the x-axis refer to the sampling points, with 1 
representing the initial baseline endoscopy and subsequent visits referred by 
increasing numbers (surveillance intervals are variable).  
Figure 4: Light micrographs of representative examples of expression of OR3A4 via 
IHC of non-progressor (A=10X view, B=40X view) and progressor (C=10X view, 
D=40X) view 
  
 Table 1: Top20 array identified CpG sites with methylation variation between non-
dysplastic samples which progress to OADC vs those which remain static 
Key: Probe ID – the Illumina cg probe ID from the Illumina manifest, T = the t value – the size of the difference 
relative to the variation in the sample, p-value = the raw p-value, not corrected for multiple testing, Adjusted p-
value = the p-value corrected for multiple testing 
 
Probe ID t P.Value Adj.P.Value Gene Name 
cg09890332 -12.26 2.02E-08 0.0031 OR3A4 
cg24007926 -11.05 6.84E-08 0.0032 NA 
cg17337672 -10.95 7.54E-08 0.0032 FGFR2 
cg02226469 -10.88 8.17E-08 0.0032 NA 
cg17433294 -10.51 1.22E-07 0.0038 NMUR2 
cg18479711 -10.31 1.52E-07 0.0039 HDAC4 
cg09011162 -10.15 1.82E-07 0.0040 LMF1 
cg19733463 -9.83 2.61E-07 0.0045 NMUR1 
cg16150571 -9.64 3.26E-07 0.0045 SNORD116-22 
cg24424217 -9.62 3.35E-07 0.0045 ZNF511 
cg13164993 -9.57 3.52E-07 0.0045 RBP3 
cg14019464 -9.53 3.70E-07 0.0045 TRIB3 
cg24581378 -9.53 3.71E-07 0.0045 ZAP70 
cg05230642 -9.36 4.54E-07 0.0051 SNORD115-14 
cg12297814 -9.26 5.08E-07 0.0052 IGFN1 
cg11231240 -9.23 5.33E-07 0.0052 NA 
cg11864327 -8.96 7.40E-07 0.0063 ZFP2 
 cg16771467 -8.92 7.78E-07 0.0063 ATP8B1 
cg17304276 -8.88 8.14E-07 0.0063 CUX2 
cg11443888 -8.86 8.36E-07 0.0063 TMEM151B 
 
  
 Table 2: Table of differentially methylated regions (DMR) 
DMR ID Probe ID Probe level 
adjusted p-
value 
Chromosome Gene Start of 
DMR (bp) 
End of 
DMR (bp) 
Size 
in bp 
Change in 
methylation 
P-
value 
for 
DMR 
1 cg21273584 0.014 2 NA 502999 503195 197 -34% 7.69E-
04 
1 cg00854591 0.045 2 NA 502999 503195 197 -16% 7.69E-
04 
1 cg11573608 0.014 2 NA 502999 503195 197 -27% 7.69E-
04 
2 cg25568703 0.047 5 NA 8216903 8217655 753 -25% 1.27E-
03 
2 cg25016964 0.039 5 NA 8216903 8217655 753 -22% 1.27E-
03 
2 cg17642708 0.021 5 NA 8216903 8217655 753 -33% 1.27E-
03 
3 cg10788901 0.172 10 FGFR2 123352704 123355661 2958 -27% 4.79E-
03 
3 cg14856220 0.044 10 FGFR2 123352704 123355661 2958 -24% 4.79E-
03 
3 cg17337672 0.003 10 FGFR2 123352704 123355661 2958 -47% 4.79E-
03 
3 cg02412684 0.031 10 FGFR2 123352704 123355661 2958 -38% 4.79E-
03 
3 cg06791446 0.058 10 FGFR2 123352704 123355661 2958 -13% 4.79E-
03 
 3 cg22633036 0.581 10 FGFR2 123352704 123355661 2958 -4% 4.79E-
03 
  
